Table 1.
Baseline characteristics
| OT (n=291) | PI-mono (n=296) | Total (n=587) | ||
|---|---|---|---|---|
| Demographic and clinical characteristics | ||||
| Age (years) | 43 (37–49, 23–75) | 45 (39–50, 23–67) | 44 (38–49, 23–75) | |
| Route of infection | ||||
| Homosexual | 175 (60%) | 176 (59%) | 351 (60%) | |
| Heterosexual | 108 (37%) | 108 (36%) | 216 (37%) | |
| Other | 8 (3%) | 12 (4%) | 20 (3%) | |
| Female | 64 (22%) | 73 (25%) | 137 (23%) | |
| Ethnic origin | ||||
| White | 206 (71%) | 195 (66%) | 401 (68%) | |
| Black | 73 (25%) | 90 (30%) | 163 (28%) | |
| Other | 12 (4%) | 11 (4%) | 23 (4%) | |
| Hepatitis C virus antibody positive | 7 (2%) | 14 (5%) | 21 (4%) | |
| HIV disease status | ||||
| Previous AIDS-defining illness | 59 (20%) | 57 (19%) | 116 (20%) | |
| Nadir CD4 count (cells per μL) | 181 (90–258) | 170 (80–239) | 178 (86–250) | |
| Baseline CD4 count (cells per μL) | 512 (386–658) | 516 (402–713) | 513 (392–682) | |
| Undetectable baseline HIV viral load | 276 (95%) | 279 (94%) | 555 (95%) | |
| Duration of undetectable viral load (months) | 36 (17–62) | 38 (22–66) | 37 (20–63) | |
| ART history | ||||
| Years since ART started | 3·9 (2·0–6·4) | 4·2 (2·4–6·9) | 4·0 (2·2–6·7) | |
| On first ART combination | 91 (31%) | 96 (32%) | 187 (32%) | |
| Number of drugs ever received | 5 (3–6) | 4 (3–6) | 4 (3–6) | |
| NNRTI at entry | ||||
| Any | 157 (54%) | 157 (53%) | 314 (53%) | |
| Efavirenz | 115 (40%) | 115 (39%) | 230 (39%) | |
| Nevirapine | 42 (14%) | 39 (13%) | 81 (14%) | |
| Etravirine | 0 | 3 (1%) | 3 (1%) | |
| Protease inhibitor at entry | ||||
| Any | 134 (46%) | 139 (47%) | 273 (47%) | |
| Atazanavir | 59 (20%) | 59 (20%) | 118 (20%) | |
| Lopinavir | 28 (10%) | 49 (17%) | 77 (13%) | |
| Darunavir | 24 (8%) | 13 (4%) | 37 (6%) | |
| Saquinavir | 16 (5%) | 15 (5%) | 31 (5%) | |
| Fosamprenavir | 7 (2%) | 3 (1%) | 10 (2%) | |
| NRTIs at entry | ||||
| Any | 291 (100%) | 296 (100%) | 587 (100%) | |
| Emtricitabine and tenofovir | 190 (65%) | 180 (61%) | 370 (63%) | |
| Lamivudine and abacavir | 80 (27%) | 82 (28%) | 162 (28%) | |
| Other | 21 (7%) | 34 (11%) | 55 (9%) | |
| Resistance | ||||
| Resistance test result available before trial | 181 (62%) | 165 (56%) | 346 (59%) | |
| Intermediate-level or high-level resistance to NRTI or NNRTI before trial* | 4 (2%) | 7 (4%) | 11 (3%) | |
Data are median (IQR, range), median (IQR), or n (%). OT=ongoing triple therapy. PI-mono=protease inhibitor monotherapy. ART=antiretroviral therapy. NNRTI=non-nucleoside reverse transcriptase inhibitor. NRTI=nucleoside reverse transcriptase inhibitor.
*
Percentages are of the numbers of patients with resistance test results available before the trial.